Details Basic Details Approval Date Friday, June 19, 2020 Original Posting Date Wednesday, August 3, 2022 Health Outcome(s) adverse central nervous system reactions, tardive dyskinesia Regulatory Link(s) (2) FDA Approval Package ARIA Memo Link(s) Sentinel Drug Study: Gimoti (Metoclopramide Nasal Spray) & Tardive Dyskinesia and Adverse Central Nervous System Reactions